Cargando…
Fork Protection and Therapy Resistance in Hereditary Breast Cancer
The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recent...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041132/ https://www.ncbi.nlm.nih.gov/pubmed/29472318 http://dx.doi.org/10.1101/sqb.2017.82.034413 |
_version_ | 1783338946364702720 |
---|---|
author | Cantor, Sharon B. Calvo, Jennifer A. |
author_facet | Cantor, Sharon B. Calvo, Jennifer A. |
author_sort | Cantor, Sharon B. |
collection | PubMed |
description | The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recently, independent of DNA repair, functions in the replication stress response have come to light, providing insight as to how the BRCA-FA pathway also balances genome preservation with proliferation. The BRCA-FA proteins associate with the replisome and contribute to the efficiency and recovery of replication following perturbations that slow or arrest DNA replication. Although the full repertoire of functions in the replication stress response remains to be elucidated, the function of BRCA1 and BRCA2 in protecting stalled replication forks contributes along with HR to the sensitivity of BRCA-associated tumors to chemotherapy. Moreover, chemoresistance evolves from restoration of either HR and/or fork protection. Although mechanisms underlying the restoration of HR have been characterized, it remains less clear how restoration of fork protection is achieved. Here, we outline mechanisms of “rewired” fork protection and chemotherapy resistance in BRCA cancer. We propose that mechanisms are linked to permissive replication that limits fork remodeling and therefore opportunities for fork degradation. Combating this chemoresistance mechanism will require drugs that inactivate replication bypass mechanisms. |
format | Online Article Text |
id | pubmed-6041132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60411322018-07-11 Fork Protection and Therapy Resistance in Hereditary Breast Cancer Cantor, Sharon B. Calvo, Jennifer A. Cold Spring Harb Symp Quant Biol Article The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recently, independent of DNA repair, functions in the replication stress response have come to light, providing insight as to how the BRCA-FA pathway also balances genome preservation with proliferation. The BRCA-FA proteins associate with the replisome and contribute to the efficiency and recovery of replication following perturbations that slow or arrest DNA replication. Although the full repertoire of functions in the replication stress response remains to be elucidated, the function of BRCA1 and BRCA2 in protecting stalled replication forks contributes along with HR to the sensitivity of BRCA-associated tumors to chemotherapy. Moreover, chemoresistance evolves from restoration of either HR and/or fork protection. Although mechanisms underlying the restoration of HR have been characterized, it remains less clear how restoration of fork protection is achieved. Here, we outline mechanisms of “rewired” fork protection and chemotherapy resistance in BRCA cancer. We propose that mechanisms are linked to permissive replication that limits fork remodeling and therefore opportunities for fork degradation. Combating this chemoresistance mechanism will require drugs that inactivate replication bypass mechanisms. 2018-02-22 2017 /pmc/articles/PMC6041132/ /pubmed/29472318 http://dx.doi.org/10.1101/sqb.2017.82.034413 Text en http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited. |
spellingShingle | Article Cantor, Sharon B. Calvo, Jennifer A. Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title | Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title_full | Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title_fullStr | Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title_full_unstemmed | Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title_short | Fork Protection and Therapy Resistance in Hereditary Breast Cancer |
title_sort | fork protection and therapy resistance in hereditary breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041132/ https://www.ncbi.nlm.nih.gov/pubmed/29472318 http://dx.doi.org/10.1101/sqb.2017.82.034413 |
work_keys_str_mv | AT cantorsharonb forkprotectionandtherapyresistanceinhereditarybreastcancer AT calvojennifera forkprotectionandtherapyresistanceinhereditarybreastcancer |